Titre : International Liver Congress/Healio - Three HCV drugs may not be better than two
link : International Liver Congress/Healio - Three HCV drugs may not be better than two
International Liver Congress/Healio - Three HCV drugs may not be better than two
Expert: Three HCV drugs may not be better than twoAMSTERDAM — The benefits of both double and triple direct-acting antiviral therapy combinations depend on myriad patient and disease factors, according to findings presented at the International Liver Congress.
Pawlotsky ran down a laundry list of agents in the pipeline, including NS5A inhibitors odalasvir (Achillion), pibrentasvir (AbbVie), and ruzasvir (Merck), and NS5B inhibitors AL-335 (Achillion), pibrentasvir (AbbVie) and uprifosbuvir (Merck). Although trials are currently underway, he suggested that ruzasvir has improved on previous compounds. “This drug has a virtually no resistance in vitro,” he said, noting that the resistance barrier was lower than Daklinza (daclatasvir, Bristol-Myers Squibb) or ledipasvir (Gilead). “You can see we’re making progress.”
Continue reading....
Recommended Reading
See more from International Liver Congress
Thus articles International Liver Congress/Healio - Three HCV drugs may not be better than two
that is all articles International Liver Congress/Healio - Three HCV drugs may not be better than two This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article International Liver Congress/Healio - Three HCV drugs may not be better than two the link address https://newsaninpiration.blogspot.com/2017/04/international-liver-congresshealio.html
0 Response to "International Liver Congress/Healio - Three HCV drugs may not be better than two"
Post a Comment